Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NRXP

NRXP - NRx Pharmaceuticals, Inc. Stock Price, Fair Value and News

$3.09+0.11 (+3.69%)
Market Closed

4/100

NRXP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

4/100

NRXP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

NRXP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NRXP Price Action

Last 7 days

5.1%

Last 30 days

43.1%

Last 90 days

47.1%

Trailing 12 Months

48.6%

NRXP RSI Chart

NRXP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NRXP Valuation

Market Cap

86.8M

Price/Earnings (Trailing)

-1.88

Price/Sales (Trailing)

141.06

EV/EBITDA

-1.59

Price/Free Cashflow

-5.73

NRXP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

NRXP Fundamentals

NRXP Revenue

Revenue (TTM)

494.0K

NRXP Earnings

Earnings (TTM)

-38.1M

Earnings Growth (Yr)

-262.91%

Earnings Growth (Qtr)

66.5%

NRXP Profitability

EBT Margin

-8047.37%

Return on Equity

147.78%

Return on Assets

-253.81%

Free Cashflow Yield

-17.44%

NRXP Investor Care

Shares Dilution (1Y)

132.33%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20240000
2023310.3K371.5K432.8K494.0K
20222.5M1.4M0249.0K
20210003.7M
Get all data in R, Python etc through our Historical Stock Data APIs

About NRx Pharmaceuticals, Inc.

NRXP
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
0
 CEO
 WEBSITEnrxpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology

NRx Pharmaceuticals, Inc. Frequently Asked Questions

NRXP is the stock ticker symbol of NRx Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri May 01 2026, market cap of NRx Pharmaceuticals, Inc. is 86.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri May 01 2026, NRXP's PE ratio (Price to Earnings) is -1.88 and Price to Sales (PS) ratio is 141.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NRXP PE ratio will change depending on the future growth rate expectations of investors.